April 1, 2013
By:
G. Steven Burrill
Early-stage companies are finding alternatives to venture capital.
|
January 1, 2013
By:
G. Steven Burrill
A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.
|
October 1, 2012
By:
G. Steven Burrill
A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.
|
July 1, 2012
By:
G. Steven Burrill
Collaborative R&D models coincide with new ways to fund translational research.
|
April 1, 2012
By:
G. Steven Burrill
Better news about the global economy buoys life-sciences funding.
|
January 1, 2012
By:
G. Steven Burrill
Greater emphasis on focus and efficiency for companies as market demands value in 2012.
|
October 1, 2011
By:
G. Steven Burrill
Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings
|
July 1, 2011
By:
G. Steven Burrill
Strong pipelines, approvals, and deals drive up market cap.
|
|
